Status:
ACTIVE_NOT_RECRUITING
Liraglutide Effect in Atrial Fibrillation
Lead Sponsor:
University of Miami
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The goal (or purpose) of this study is to evaluate (study) a new way to stabilize (steady) the activity between the fat deposits surrounding the heart and the left atrium. To reduce the amount of EAT...
Eligibility Criteria
Inclusion
- Male and female, age 18 or older
- Persistent AF defined as continuous AF sustained beyond 7 days (or AF with the decision to cardiovert before 7 days of enrollment or Paroxysmal AF defined as recurrent AF (≥2 episodes) that terminates spontaneously within 7 days
- BMI ≥27 kg/m2
- Patient wishes to undergo a catheter ablation procedure for the treatment of atrial fibrillation
- Receiving follow-up care at the University of Miami
Exclusion
- Inability to sign an informed consent
- Patients with longstanding persistent atrial fibrillation of more than 3 years
- Prior ablation for atrial fibrillation
- Patients not appropriate candidates for catheter ablation such as those with AF due to acute or chronic precipitating medical conditions, for example, hypothyroidism and hyperthyroidism, significant pulmonary disease, pulmonary embolism, left atrial thrombus, class IV heart failure)
- Patients with a life expectancy \<1 year
- Patients with a serious medical condition (for example, recent cancer with chemotherapy or radiation therapy within 4 weeks before entering the study) who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Known contraindications to Liraglutide, such as the previous history of pancreatitis or medullary thyroid carcinoma
- Personal or family history of multiple endocrine neoplasias
- Known serious hypersensitivity reaction to Liraglutide
- Patients using, glitazones, sodium-glucose transporters 2 inhibitors (SGLT2i), other GLP-1 analogs, or DPP4 inhibitors
- Type 1 diabetes, defined by American Diabetes Association criteria, history of diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes due to pancreatitis or pancreatectomy
- Poorly controlled type 2 diabetes with HbA1c \> 10%
- Pregnant women
- Women who are breast-feeding or intend to become pregnant
Key Trial Info
Start Date :
March 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03856632
Start Date
March 18 2019
End Date
December 31 2025
Last Update
March 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami
Miami, Florida, United States, 33136